• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Chronic Spontaneous Urticaria
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Article

FDA approves new drug application for Pliaglis

The Food and Drug Administration has approved a supplemental new drug application for Pliaglis (lidocaine 7 percent, tetracaine 7 percent), a topical anesthetic cream.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!
Related Videos
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
FDA Launches Agency-Wide AI Rollout by 2025
May 8th 2025

FDA Launches Agency-Wide AI Rollout by 2025

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine
March 31st 2025

Derm Dispatch: A Comprehensive Guide to Managing Eczema with Integrative Medicine

Evaluating Dupilumab and Upadacitinib for Head and Neck AD
May 8th 2025

Evaluating Dupilumab and Upadacitinib for Head and Neck AD

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Daily Derm Times: May 7, 2025
May 8th 2025

Daily Derm Times: May 7, 2025

Building Trust Through Cultural Competency in Aesthetic Dermatology
May 7th 2025

Building Trust Through Cultural Competency in Aesthetic Dermatology

© 2025 MJH Life Sciences

All rights reserved.